RAD1901: A novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models

Anti-Cancer Drugs

Volumn 26, Issue 9, 2015, Pages 948-956

  Garner, Fiona ^a   Shomali, Maysoun ^a   Paquin, Dotty ^b   Lyttle, C Richard ^a   Hattersley, Gary ^a  

^a Radius Health Inc   (United States)

^b PFIZER INC   (United States)

Author keywords

Anticancer activity; Blood brain barrier; Breast cancer; Estrogen receptor inhibition; Selective estrogen receptor degraders; Selective estrogen receptor modulators; Tissue selectivity

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN; FULVESTRANT; RAD 1901; RALOXIFENE; TAMOXIFEN; UNCLASSIFIED DRUG; ANTHRANILIC ACID DERIVATIVE; CARBANILAMIDE DERIVATIVE; ESTROGEN RECEPTOR ALPHA; N-(4-(4,6-DIMETHYL-2-PYRIMIDINYLOXY)-3-METHYLPHENYL)-N'-(2-(DIMETHYLAMINO))BENZOYLUREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BONE DENSITY; BONE MASS; BRAIN METASTASIS; BREAST CANCER; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BINDING; DRUG IDENTIFICATION; ENDOMETRIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; INTRACRANIAL TUMOR; MCF 7 CELL LINE; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RAT; RECEPTOR BINDING ASSAY; TUMOR XENOGRAFT; UTERINE TISSUE; UTERUS WEIGHT; ANIMAL; BINDING COMPETITION; BRAIN NEOPLASMS; BREAST NEOPLASMS; CANCER TRANSPLANTATION; DRUG EFFECTS; METABOLISM; NUDE MOUSE; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; OVARIECTOMY; PATHOLOGY; PATHOPHYSIOLOGY; SECONDARY; SPRAGUE DAWLEY RAT; UTERUS; XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; BONE DENSITY; BRAIN NEOPLASMS; BREAST NEOPLASMS; CELL PROLIFERATION; ESTROGEN RECEPTOR ALPHA; FEMALE; HETEROGRAFTS; MCF-7 CELLS; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORTHO-AMINOBENZOATES; OSTEOPOROSIS; OVARIECTOMY; PHENYLUREA COMPOUNDS; RATS, SPRAGUE-DAWLEY; UTERUS;

EID: 84940933249     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000271     Document Type: Article

References (22)

1. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006; 354:270-282.
2. Ariazi EA, Ariazi JL, Cordera F, Jordan VC. Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem 2006; 6:181-202.
3. Stein RA, McDonnell DP. Estrogen-related receptor alpha as a therapeutic target in cancer. Endocr Relat Cancer 2006; 13 (Suppl 1):S25-S32.
4. Yue W, Yager JD, Wang JP, Jupe ER, Santen RJ. Estrogen receptordependent and independent mechanisms of breast cancer carcinogenesis. Steroids 2013; 78:161-170.
5. Stingl J. Estrogen and progesterone in normal mammary gland development and in cancer. Horm Cancer 2011; 2:85-90.
6. Pinkerton JV, Thomas S. Use of SERMs for treatment in postmenopausal women. J Steroid Biochem Mol Biol 2014; 142:142-154.
7. Swaby RF, Sharma CG, Jordan VC. SERMs for the treatment and prevention of breast cancer. Rev Endocr Metab Disord 2007; 8:229-239.
8. Jordan VC. Chemoprevention of breast cancer with selective oestrogenreceptor modulators. Nat Rev Cancer 2007; 7:46-53.
9. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptorpositive advanced breast cancer. J Clin Oncol 2010; 28:4594-4600.
10. Van Kruchten M, de Vries EG, Glaudemans AW, van Lanschot MC, van Faassen M, Kema IP, et al. Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer. Cancer Discov 2015; 5:72-81.
11. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240:889-895.
12. Singh RR, Kumar R. Steroid hormone receptor signaling in tumorigenesis. J Cell Biochem 2005; 96:490-505.
13. McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science 2002; 296:1642-1644.
14. Burns KA, Korach KS. Estrogen receptors and human disease: an update. Arch Toxicol 2012; 86:1491-1504.
15. Herynk MH, Fuqua SA. Estrogen receptors in resistance to hormone therapy. Adv Exp Med Biol 2007; 608:130-143.
16. Kalu DN. The ovariectomized rat model of postmenopausal bone loss. Bone Miner 1991; 15:175-191.
17. Lai A, Kahraman M, Govek S, Nagasawa J, Bonnefous C, Julien J, et al. Identification of GDC-0810 (ARN-810), an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts. J Med Chem 2015; 58:4888-4904.
18. Wardell SE, Marks JR, McDonnell DP. The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biochem Pharmacol 2011; 82:122-130.
19. Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol 2013; 8:135-155.
20. Hattersley G, David F, Harris A, Clarkin M, Banks K, Williams G, et al. RAD1901, a novel tissue-selective estrogen receptor degrader (SERD) demonstrates estrogen receptor engagement in a phase 1 clinical study. Paper presented at: San Antonio Breast Cancer Meeting; 9-13 December 2014; San Antonio, Texas, USA.
21. Fulvestrant Prescribing Information. AstraZeneca website. Available at: http://www1.astrazeneca-us.com/pi/faslodex.pdf. [Accessed 6 May 2015].
22. Coleman RE. Hormone- and chemotherapy-induced bone loss in breast cancer. Oncology (Williston Park) 2004; 18 (5 Suppl 3):16-20.